These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 29451870)

  • 1. Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
    Galizzi N; Galli L; Poli A; Gianotti N; Carini E; Bigoloni A; Tambussi G; Nozza S; Lazzarin A; Castagna A; Mancusi D; Termini R
    PLoS One; 2018; 13(2):e0191300. PubMed ID: 29451870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
    Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
    Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
    PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
    Ho S; Wong JG; Ng OT; Lee CC; Leo YS; Lye DCB; Wong CS
    AIDS Res Ther; 2020 May; 17(1):23. PubMed ID: 32438914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
    HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
    Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS).
    Lim ZC; Hoo GS; Ang JH; Teng CB; Ang LW; Lee CC; Leo YS; Law HL; Ng OT; Wong CS
    AIDS Res Ther; 2021 Nov; 18(1):80. PubMed ID: 34724931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
    Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
    Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
    Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
    Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
    Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
    Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.
    Curran A; Rojas J; Cabello A; Troya J; Imaz A; Domingo P; Martinez E; Ryan P; Górgolas M; Podzamczer D; Knobel H; Gutiérrez F; Ribera E
    J Antimicrob Chemother; 2016 Dec; 71(12):3510-3514. PubMed ID: 27591292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.
    Llibre JM; Cozzi-Lepri A; Pedersen C; Ristola M; Losso M; Mocroft A; Mitsura V; Falconer K; Maltez F; Beniowski M; Vullo V; Hassoun G; Kuzovatova E; Szlavik J; Kuznetsova A; Stellbrink HJ; Duvivier C; Edwards S; Laut K; Paredes R;
    Medicine (Baltimore); 2016 Oct; 95(40):e5020. PubMed ID: 27749561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
    Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon ED; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P;
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):693-701. PubMed ID: 15167288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
    Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.